TB vaccine with a long view

摘要

Tuberculosis (TB) infection can enter an asymptomatic latent' phase and re-emerge later. The only approved TB vaccine,BCG, targets just the disease's early, active stage. A vaccine candidate, H56, that contains an antigen from the latent phase affords mice longer- lasting protection against the disease than does BCG, report Claus Aagaard and Peter Andersen at the Statens Serum Institute in Copenhagen and their co-workers.